Science
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 – EurekAlert
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab…
What The Study Did: This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs combination bamlanivimab and etesevimab vs placebo on change in day 11 severe acute respiratory syndrome coronavirus 2 viral load in patients with mild to moderate COVID-19.
Authors: Daniel M. Skovronsky, M.D., Ph.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at…
-
Noosa News20 hours agoThree people charged over alleged highway robbery of tourist near Cardwell
-
Noosa News20 hours agoBrisbane aerobridges strike again, this time damaging a Fijian jet
-
Noosa News23 hours agoWarmer seas could bring more sharks to popular beaches
-
General22 hours agoOne week in the NT’s Youth Justice Court shows effects of tough bail laws